Dr. Kennedy on Next Steps With SIRFLOX Trial in Liver-Metastatic CRC

Andrew Kennedy, MD
Published: Tuesday, Apr 25, 2017



Andrew Kennedy, MD, physician-in-chief and radiation oncologist at Sarah Cannon Research Institute, discusses the next steps following the SIRFLOX clinical trial for patients with liver-metastatic colorectal cancer (CRC).


Andrew Kennedy, MD, physician-in-chief and radiation oncologist at Sarah Cannon Research Institute, discusses the next steps following the SIRFLOX clinical trial for patients with liver-metastatic colorectal cancer (CRC).



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x